Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills

Merck KGaA's multiple sclerosis pill Mavenclad has finally won FDA approval, but some analysts think its US label, stipulating second-line use in relapsing MS but not in patients with clinically isolated syndrome, may hurt its uptake there.